Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 6, 2008, Pages 1085-1090

  Ruiz, M ^a   Salvador, J ^b   Bayo, J ^c   Lomas, M ^d   Moreno, A ^e   Valero, M ^a   Bernabe R ^b   Vicente, D ^c   Jimenez J ^a   Lopez Ladron A ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^c HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^d HOSPITAL INFANTA CRISTINA   (Spain)

^e HOSPITAL DE JEREZ   (Spain)

Author keywords

Carboplatin; Metastatic breast cancer; Paclitaxel; Trastuzumab

Indexed keywords

CARBOPLATIN; PACLITAXEL; TRASTUZUMAB;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; BREAST METASTASIS; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; DISEASE PROGRESSION; FEMALE; GASTROINTESTINAL DISEASES; GENES, ERBB-2; HALF-LIFE; HEMATOLOGIC DISEASES; HUMANS; MIDDLE AGED; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; SURVIVAL ANALYSIS;

EID: 51849112467     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0709-7     Document Type: Article

References (55)

1. RT Greenlee T Murray S Bolden PA Wingo 2000 Cancer statistics CA Cancer J Clin 50 7
2. GM Clark GW Sledge Jr CK Osborne WL McGuire 1987 Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients J Clin Oncol 5 55 61
3. Henderson IC (1991) Chemotherapy for metastatic disease. In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast diseases, 2nd edn. JB Lippincott, Philadelphia
4. GW Sledge Jr PJ Loehrer Sr BJ Roth LH Einhorn 1988 Cisplatin as first-line therapy for metastatic breast cancer J Clin Oncol 6 1811 1814
5. GW Sledge Jr BJ Roth 1989 Cisplatin in the management of breast cancer Semin Oncol 16 110 115
6. M Martin E Diaz-Rubio A Casado 1992 Carboplatin: an active drug in metastatic breast cancer J Clin Oncol 10 433 437
7. ME O'Brien DC Talbot IE Smith 1993 Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule J Clin Oncol 11 2112 2117
8. GN Hortobagyi 1993 Mitomycin: its evolving role in the treatment of breast cancer Oncology 50 1 8 (review)
9. GP Canellos SJ Pocock SG Taylor 1976 Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with l-phenylalanine mustard Cancer 38 1882 1886
10. RT Chlebowski LE Irwin RP Pugh 1979 Survival of patients with metastatic breast cancer treated with either combination or sequential chemotherapy Cancer Res 39 4503 4506
11. B Hoogstraten SL George B Samal 1976 Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study Cancer 38 13 20
12. JM Bull DC Tormey SH Li 1978 A randomized comparative trial of Adriamycin versus methotrexate in combination drug therapy Cancer 41 1649 1657
13. RP A'Hern IE Smith SR Ebbs 1993 Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens Br J Cancer 67 801 805
14. J Aisner V Weinberg M Perloff 1987 Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B J Clin Oncol 5 1523 1533
15. JF Bishop J Dewar GC Toner 1999 Taxol Investigational Trials Group ANZ. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer J Clin Oncol 17 2355 2365
16. AY Chang L Boros R Asbury L Hui J Rubins 1997 Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer Semin Oncol 24 S17 S71
17. TM Loffler 1998 Is there a place for "dose-dense" weekly schedules of the taxoids? Semin Oncol 25 32 34
18. AD Seidman CA Hudis J Albanel 1998 Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer J Clin Oncol 16 3353 3361 (review)
19. E Munzone G Capri F Fulfaro 1994 Paclitaxel by 3 h schedule in relapsed breast cancer resistant to anthracyclines Ann Oncol 5 42 (abstract)
20. X Pivot L Asmar GN Hortobagyi 1999 The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer Int J Oncol 15 381 386
21. GN Hortobagyi 1997 Paclitaxel-based combination chemotherapy for breast cancer Oncology 11 29 37 (review)
22. KD Miller GW Sledge Jr 1999 Taxanes in the treatment of breast cancer: a prodigy comes of age Cancer Invest 17 121 136
23. P Pouillart P Fumoleau G Romieu 1999 Final results of a phase II randomized, parallel study of doxorubicin/cyclophosphamide and doxorubicin/Taxol (paclitaxel) as neoadjuvant treatment of local-regional breast cancer Proc Am Soc Clin Oncol 18 73a (abstract)
24. Cassier PA, Chabaud S, Trillet-Lenoir V et al (2007) A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study. Breast Cancer Res Treat [Epub ahead of print]
25. G Frasci P Comella G D'Aiuto 1998 Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study Breast Cancer Res Treat 49 13 26
26. KA Gelmon SE O'Reilly AW Tolcher 1996 Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer J Clin Oncol 14 1185 1191
27. JA Sparano D Neuberg JH Glick 1997 Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: an Eastern Cooperative Oncology Group study J Clin Oncol 15 1880 1884
28. WJ McCaskill-Stevens S Fox J Harlan GW Sledge 1997 Phase I/II study of biweekly paclitaxel (P) and carboplatin (C) in the treatment of patients (pts) with stage IV breast carcinoma Proc Am Soc Clin Oncol 16 A639 (meeting abstract)
29. EA Perez LC Hartmann 1996 Paclitaxel and carboplatin for advanced breast cancer Semin Oncol 23 41 45
30. U Klaassen H Wilke A Harstrick S Seeber 1998 Fluorouracil-based combinations in the treatment of metastatic breast cancer Oncology (Williston Park) 12 31 35
31. B Nicholson D Paul Y Shyr 1997 Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer: a Vanderbilt Cancer Center phase II trial Semin Oncol 24 S11 S23
32. G Cocconi A Mambrini G Vasini 1998 Vinorelbine combined with paclitaxel, administered in a continuous 96-hour IV infusion, in pretreated advanced breast cancer patients Proc Am Soc Clin Oncol 17 208 (abstract)
33. A Michelotti A Gennari B Salvadori 1996 Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients Semin Oncol 23 38 40
34. DJ Slamon W Godolphin LA Jones 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 707 712
35. DJ Slamon GM Clark SG Wong 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 182
36. R Seshadri FA Firgaira DJ Horsfall 1993 Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group J Clin Oncol 11 1936 1942
37. MF Press L Bernstein PA Thomas 1997 HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas J Clin Oncol 15 2894 2904
38. MJ Ellis A Coop B Singh 2001 Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial J Clin Oncol 19 3808 3816
39. MJ Piccart A Di Leo A Hamilton 2000 HER2: a 'predictive factor' ready to use in the daily management of breast cancer patients? Eur J Cancer 36 1755 1761
40. MD Pegram GE Konecny C O'Callaghan 2004 Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer J Natl Cancer Inst 96 739 749
41. C Vogel MA Cobleigh D Tripathy 2002 Efficacy and safety of trastuzumab as single agent first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 3 719 726
42. DJ Slamon B Leyland-Jones S Shak 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792
43. MD Pegram A Lipton DF Hayes 1998 Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpresing metastatic breast cancer refractory to chemotherapy treatment J Clin Oncol 16 2659 2671
44. G Fountzilas D Tsavdaridis A Kalogera-Fountzila 2002 Weekly paclitaxel as first line treatment and trastuzumab in patients with advanced breast cancer Ann Oncol 11 50 57
45. JM Nabholtz J Crown L Yonemoto 2000 Results of two open label multicentre pilot phase II trials with herceptin in combination with docetaxel and platinum salts (cis- or carboplatin) as therapy for advanced breast cancer in women overexpressing HER2 Breast Cancer Res Treat 64 1 82
46. Yardley DA, Greco FA, Hainsworth JD et al (2002) Final results of the pearl cancer research network first line trial of weekly paclitaxel/carboplatin/ trastuzumab in metastatic breast cancer. In: 25th Annual San Antonio breast cancer symposium
47. N Robert B Leyland-Jones L Asmar 2006 Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer J Clin Oncol 24 18 2786 2792
48. CB Washington G Lieberman P Liu 2002 A population pharmacokinetic model for Trastuzumab following weekly dosing Clin Pharmacol Ther 71 12
49. Charoin JE, Jacqmin P, Banken L et al (2004) Population pharmacokinetic analysis of trastuzumab following long-term administration using different regimens. Population Approach Group (PAGE), Uppsala. http://www.page-meeting.org
50. J Baselga X Carbonell NJ Castaneda-Soto 2005 Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule J Clin Oncol 23 2162 2171
51. B Leyland-Jones K Gelmon JP Ayoub 2003 Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel J Clin Oncol 21 3965 3971
52. CE Geyer J Foster D Lindquist 2006 Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733 2743
53. RJ Pietras BM Fendly VR Chazin MD Pegram SB Howell DJ Slamon 1994 Antibody to her2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells Oncogene 9 1829 1838
54. Pegram M, Forbes J, Pienkowski T et al (2007) BCIRG 007: first overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). J Clin Oncol, 2007 ASCO annual meeting proceedings part I, vol 25, no. 18S (June 20 Supplement): LBA1008
55. EA Perez VJ Suman KM Rowland 2005 Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252 Clin Breast Cancer 6 5 425 432